Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber | NCT01222299 | Trialant
CompletedInterventionalPhase 1Phase 2Updated Oct 5, 2020
Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
ClinicalTrials.gov ID
NCT01222299
Lead Sponsor
Bausch & Lomb IncorporatedINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 1Phase 2
Enrollment
89Actual
Last Update Posted
Oct 5, 2020Actual
Start Date
May 2010
Primary Completion Date
Aug 2010Actual
Completion Date
Aug 2010Actual
Brief Summary
The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.
Seasonal Allergic Rhinitis
bepotastine besilate nasal product - low dose
bepotastine besilate nasal product - medium dose
bepotastine besilate nasal product - high dose
placebo comparator nasal product
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects 18 to 65 years of age with a positive skin prick test with ragweed allergen